Anne Ml Jansen

11PUBLICATIONS
71CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedMolecular targetsInnate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 01, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn

|Aug 15, 2025
Cemento-osseous dysplasia with a NOTCH4 mutation: a case report.

Gerben E Breimer, Nard G Janssen, Anne M L Jansen

|Oct 01, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.

Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn

|Jul 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia

|Apr 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek

Pageof 2